BG108073A - Специфични макролидни съединения за конюгати на имунна клетка с противовъзпалителни съединения за подобрен клетъчен обект за противовъзпалителна терапия - Google Patents

Специфични макролидни съединения за конюгати на имунна клетка с противовъзпалителни съединения за подобрен клетъчен обект за противовъзпалителна терапия Download PDF

Info

Publication number: BG108073A
Authority: BG; Bulgaria
Prior art keywords: hydrogen; group; fluorine; represented; methyl
Prior art date: 2001-01-09

Application number

BG108073A

Other languages

Bulgarian (bg)

English (en)

Inventor

Mladen Mercep

Milan Mesic

Linda Tomaskovic

Marijana Komac

Boska Hrvacic

Stribor Markovic

Original Assignee

Pliva-Istrazivacki Institut D.O.O.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-09

Filing date

2003-08-07

Publication date

2005-05-31

2003-08-07 Application filed by Pliva-Istrazivacki Institut D.O.O. filed Critical Pliva-Istrazivacki Institut D.O.O.

2005-05-31 Publication of BG108073A publication Critical patent/BG108073A/bg

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 89
239000003120 macrolide antibiotic agent Substances 0.000 title claims abstract description 37
230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 21
210000002865 immune cell Anatomy 0.000 title description 2
238000011861 anti-inflammatory therapy Methods 0.000 title 1
230000001413 cellular effect Effects 0.000 title 1
230000008685 targeting Effects 0.000 title 1
150000003431 steroids Chemical class 0.000 claims abstract description 35
238000011282 treatment Methods 0.000 claims abstract description 11
241001465754 Metazoa Species 0.000 claims abstract description 8
208000027866 inflammatory disease Diseases 0.000 claims abstract description 6
238000009825 accumulation Methods 0.000 claims abstract description 5
239000000825 pharmaceutical preparation Substances 0.000 claims abstract 3
239000001257 hydrogen Substances 0.000 claims description 193
229910052739 hydrogen Inorganic materials 0.000 claims description 193
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 114
150000002431 hydrogen Chemical class 0.000 claims description 66
229910052731 fluorine Inorganic materials 0.000 claims description 62
239000011737 fluorine Substances 0.000 claims description 62
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 60
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 55
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 43
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 42
239000001301 oxygen Substances 0.000 claims description 42
229910052760 oxygen Inorganic materials 0.000 claims description 42
125000004432 carbon atom Chemical group C* 0.000 claims description 40
229910052736 halogen Inorganic materials 0.000 claims description 39
150000002367 halogens Chemical class 0.000 claims description 39
125000000217 alkyl group Chemical group 0.000 claims description 32
239000000460 chlorine Substances 0.000 claims description 28
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 25
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
150000003254 radicals Chemical class 0.000 claims description 24
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 19
229910052801 chlorine Inorganic materials 0.000 claims description 19
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 19
125000000753 cycloalkyl group Chemical group 0.000 claims description 18
238000000034 method Methods 0.000 claims description 17
125000003277 amino group Chemical group 0.000 claims description 16
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 14
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 13
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 13
229910052794 bromium Inorganic materials 0.000 claims description 13
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 11
125000003118 aryl group Chemical group 0.000 claims description 10
230000015572 biosynthetic process Effects 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 10
206010061218 Inflammation Diseases 0.000 claims description 9
230000002757 inflammatory effect Effects 0.000 claims description 9
230000004054 inflammatory process Effects 0.000 claims description 9
229910000027 potassium carbonate Inorganic materials 0.000 claims description 9
239000002253 acid Substances 0.000 claims description 8
229920006395 saturated elastomer Polymers 0.000 claims description 8
230000003637 steroidlike Effects 0.000 claims description 8
238000006243 chemical reaction Methods 0.000 claims description 7
229940125773 compound 10 Drugs 0.000 claims description 7
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
208000010668 atopic eczema Diseases 0.000 claims description 6
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
238000003786 synthesis reaction Methods 0.000 claims description 6
208000011231 Crohn disease Diseases 0.000 claims description 5
150000001735 carboxylic acids Chemical class 0.000 claims description 5
238000005859 coupling reaction Methods 0.000 claims description 5
201000010099 disease Diseases 0.000 claims description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
230000004968 inflammatory condition Effects 0.000 claims description 5
230000001225 therapeutic effect Effects 0.000 claims description 5
208000006673 asthma Diseases 0.000 claims description 4
229910052799 carbon Inorganic materials 0.000 claims description 4
206010009887 colitis Diseases 0.000 claims description 4
230000008878 coupling Effects 0.000 claims description 4
238000010168 coupling process Methods 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
230000032050 esterification Effects 0.000 claims description 4
238000005886 esterification reaction Methods 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims description 3
JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 claims description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
102000004127 Cytokines Human genes 0.000 claims description 3
108090000695 Cytokines Proteins 0.000 claims description 3
201000004624 Dermatitis Diseases 0.000 claims description 3
206010012434 Dermatitis allergic Diseases 0.000 claims description 3
208000000592 Nasal Polyps Diseases 0.000 claims description 3
201000009053 Neurodermatitis Diseases 0.000 claims description 3
208000003251 Pruritus Diseases 0.000 claims description 3
201000004681 Psoriasis Diseases 0.000 claims description 3
206010039085 Rhinitis allergic Diseases 0.000 claims description 3
201000010105 allergic rhinitis Diseases 0.000 claims description 3
201000008937 atopic dermatitis Diseases 0.000 claims description 3
229940126543 compound 14 Drugs 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 3
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 3
208000028774 intestinal disease Diseases 0.000 claims description 3
230000007803 itching Effects 0.000 claims description 3
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 3
235000015320 potassium carbonate Nutrition 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 claims description 2
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims description 2
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims description 2
ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 claims description 2
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 claims description 2
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims description 2
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims description 2
YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 claims description 2
TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 claims description 2
YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 claims description 2
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims description 2
206010009900 Colitis ulcerative Diseases 0.000 claims description 2
241000282412 Homo Species 0.000 claims description 2
OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
230000004913 activation Effects 0.000 claims description 2
239000013543 active substance Substances 0.000 claims description 2
125000002252 acyl group Chemical group 0.000 claims description 2
XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims description 2
QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims description 2
239000012964 benzotriazole Substances 0.000 claims description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
229940125904 compound 1 Drugs 0.000 claims description 2
229940125797 compound 12 Drugs 0.000 claims description 2
229940125758 compound 15 Drugs 0.000 claims description 2
229940125782 compound 2 Drugs 0.000 claims description 2
229940125810 compound 20 Drugs 0.000 claims description 2
229940126086 compound 21 Drugs 0.000 claims description 2
229940126208 compound 22 Drugs 0.000 claims description 2
229940125833 compound 23 Drugs 0.000 claims description 2
229940125961 compound 24 Drugs 0.000 claims description 2
229940125846 compound 25 Drugs 0.000 claims description 2
229940125851 compound 27 Drugs 0.000 claims description 2
229940126214 compound 3 Drugs 0.000 claims description 2
229940125898 compound 5 Drugs 0.000 claims description 2
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
125000005647 linker group Chemical group 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
239000011593 sulfur Substances 0.000 claims description 2
125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
125000001153 fluoro group Chemical group F* 0.000 claims 7
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 6
125000001183 hydrocarbyl group Chemical group 0.000 claims 6
239000011261 inert gas Substances 0.000 claims 5
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims 1
ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims 1
YHVUVJYEERGYNU-UHFFFAOYSA-N 4',8-Di-Me ether-5,7,8-Trihydroxy-3-(4-hydroxybenzyl)-4-chromanone Natural products COC1(C)CC(O)OC(C)C1O YHVUVJYEERGYNU-UHFFFAOYSA-N 0.000 claims 1
KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 claims 1
229940126657 Compound 17 Drugs 0.000 claims 1
239000012190 activator Substances 0.000 claims 1
239000003513 alkali Substances 0.000 claims 1
125000004429 atom Chemical group 0.000 claims 1
AJSDVNKVGFVAQU-BIIVOSGPSA-N cladinose Chemical compound O=CC[C@@](C)(OC)[C@@H](O)[C@H](C)O AJSDVNKVGFVAQU-BIIVOSGPSA-N 0.000 claims 1
229940126142 compound 16 Drugs 0.000 claims 1
208000027744 congestion Diseases 0.000 claims 1
238000011321 prophylaxis Methods 0.000 claims 1
239000000543 intermediate Substances 0.000 description 27
239000013078 crystal Substances 0.000 description 23
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 22
210000004027 cell Anatomy 0.000 description 20
239000000243 solution Substances 0.000 description 15
239000011541 reaction mixture Substances 0.000 description 12
229910052786 argon Inorganic materials 0.000 description 11
239000000047 product Substances 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
230000000694 effects Effects 0.000 description 10
239000000741 silica gel Substances 0.000 description 10
229910002027 silica gel Inorganic materials 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
239000003480 eluent Substances 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 8
239000000203 mixture Substances 0.000 description 8
238000009472 formulation Methods 0.000 description 7
-1 hydrocarbon radical Chemical class 0.000 description 7
150000002430 hydrocarbons Chemical group 0.000 description 7
239000004215 Carbon black (E152) Substances 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
230000002411 adverse Effects 0.000 description 6
125000003342 alkenyl group Chemical group 0.000 description 6
229930195733 hydrocarbon Natural products 0.000 description 6
239000002609 medium Substances 0.000 description 6
235000011181 potassium carbonates Nutrition 0.000 description 6
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 5
239000012298 atmosphere Substances 0.000 description 5
210000001541 thymus gland Anatomy 0.000 description 5
102000000588 Interleukin-2 Human genes 0.000 description 4
108010002350 Interleukin-2 Proteins 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
238000005303 weighing Methods 0.000 description 4
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
229960004099 azithromycin Drugs 0.000 description 3
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000003246 corticosteroid Substances 0.000 description 3
229940117173 croton oil Drugs 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
229960003957 dexamethasone Drugs 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
210000003979 eosinophil Anatomy 0.000 description 3
239000012530 fluid Substances 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000006698 induction Effects 0.000 description 3
229940041033 macrolides Drugs 0.000 description 3
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
239000013641 positive control Substances 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
239000012453 solvate Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
WNXNUPJZWYOKMW-UHFFFAOYSA-N 5-bromopentanoic acid Chemical compound OC(=O)CCCCBr WNXNUPJZWYOKMW-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
101000926939 Homo sapiens Glucocorticoid receptor Proteins 0.000 description 2
102000000743 Interleukin-5 Human genes 0.000 description 2
108010002616 Interleukin-5 Proteins 0.000 description 2
102000004890 Interleukin-8 Human genes 0.000 description 2
108090001007 Interleukin-8 Proteins 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
208000030880 Nose disease Diseases 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
125000000304 alkynyl group Chemical group 0.000 description 2
150000001408 amides Chemical group 0.000 description 2
230000001640 apoptogenic effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
239000006071 cream Substances 0.000 description 2
210000005069 ears Anatomy 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
229940100602 interleukin-5 Drugs 0.000 description 2
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
229940096397 interleukin-8 Drugs 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
239000010410 layer Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
239000013642 negative control Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000013222 sprague-dawley male rat Methods 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
SVDIMNFYIPQKRW-NOVNJIRXSA-N (8R,9S,10R,13R,14S,17S)-13-(dihydroxymethyl)-10-methyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene-17-carboxylic acid Chemical compound OC([C@@]12[C@H](CC[C@H]1[C@@H]1CCC3=CC(CC[C@]3(C)[C@H]1CC2)=O)C(=O)O)O SVDIMNFYIPQKRW-NOVNJIRXSA-N 0.000 description 1
125000005999 2-bromoethyl group Chemical group 0.000 description 1
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
206010014025 Ear swelling Diseases 0.000 description 1
241000792859 Enema Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
108091006503 SLC26A1 Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
210000004404 adrenal cortex Anatomy 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
210000001132 alveolar macrophage Anatomy 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002804 anti-anaphylactic effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000012300 argon atmosphere Substances 0.000 description 1
125000005110 aryl thio group Chemical group 0.000 description 1
125000004104 aryloxy group Chemical group 0.000 description 1
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
235000021256 carbohydrate metabolism Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
UNKZPUZGUXKEGX-UHFFFAOYSA-N dichloromethane;n,n-dimethylmethanamine Chemical compound ClCCl.CN(C)C UNKZPUZGUXKEGX-UHFFFAOYSA-N 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000002795 fluorescence method Methods 0.000 description 1
229960002714 fluticasone Drugs 0.000 description 1
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000011835 investigation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229960003248 mifepristone Drugs 0.000 description 1
VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
230000000051 modifying effect Effects 0.000 description 1
230000008187 negative regulation of interleukin-2 production Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
150000002923 oximes Chemical class 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
210000004976 peripheral blood cell Anatomy 0.000 description 1
210000003024 peritoneal macrophage Anatomy 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
201000009732 pulmonary eosinophilia Diseases 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
150000003429 steroid acids Chemical class 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
125000005017 substituted alkenyl group Chemical group 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
238000001890 transfection Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
JVFFWGJAAQAIBS-UHFFFAOYSA-K trisodium 2,2-dioctyl-3-sulfonatobutanedioate Chemical compound [Na+].C(CCCCCCC)C(C(C(=O)[O-])S(=O)(=O)[O-])(C(=O)[O-])CCCCCCCC.[Na+].[Na+] JVFFWGJAAQAIBS-UHFFFAOYSA-K 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BG108073A 2001-01-09 2003-08-07 Специфични макролидни съединения за конюгати на имунна клетка с противовъзпалителни съединения за подобрен клетъчен обект за противовъзпалителна терапия BG108073A (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HR20010018A HRP20010018A2 (en)	2001-01-09	2001-01-09	Novel anti-inflammatory compounds

Publications (1)

Publication Number	Publication Date
BG108073A true BG108073A (bg)	2005-05-31

Family

ID=10947235

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108073A BG108073A (bg)	2001-01-09	2003-08-07	Специфични макролидни съединения за конюгати на имунна клетка с противовъзпалителни съединения за подобрен клетъчен обект за противовъзпалителна терапия

Country Status (23)

Country	Link
US (2)	US7446097B2 (fr)
EP (1)	EP1351973B1 (fr)
JP (1)	JP4474101B2 (fr)
CN (1)	CN1269836C (fr)
AR (1)	AR035727A1 (fr)
AT (1)	ATE462713T1 (fr)
BG (1)	BG108073A (fr)
BR (1)	BR0206347A (fr)
CA (1)	CA2434009C (fr)
CZ (1)	CZ20031825A3 (fr)
DE (1)	DE60235794D1 (fr)
EA (1)	EA007061B1 (fr)
EE (1)	EE05333B1 (fr)
ES (1)	ES2342364T3 (fr)
GE (1)	GEP20053607B (fr)
HR (1)	HRP20010018A2 (fr)
HU (1)	HUP0500180A3 (fr)
IL (1)	IL156673A0 (fr)
PL (1)	PL207636B1 (fr)
RS (1)	RS51308B (fr)
SK (1)	SK9792003A3 (fr)
UA (1)	UA77166C2 (fr)
WO (1)	WO2002055531A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002109169A (ja) *	2000-09-29	2002-04-12	Hitachi Ltd	作業支援方法並びにシステム及び作業支援方法を記録した記録媒体
AU2003219770B2 (en)	2002-02-15	2008-10-09	Merckle Gmbh	Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
US7271154B2 (en)	2002-02-15	2007-09-18	Merckle Gmbh	Antibiotic conjugates
EP1483579A4 (fr)	2002-02-15	2006-07-12	Merckle Gmbh	Conjugues de composes biologiquement actifs, methodes de preparation et d'utilisation des conjugues, formulation et applications pharmaceutiques obtenues a partir desdits conjugues
EP1521763A2 (fr) *	2002-07-08	2005-04-13	Pliva - Istrazivacki Institut d.o.o.	Substances anti-inflammatoires non steroidiennes, compositions et procedes d'utilisation de celles-ci
AU2003264917A1 (en)	2002-07-08	2004-01-23	Pliva - Istrazivacki Institut D.O.O.	Hybrid molecules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules
RS20050008A (sr) *	2002-07-08	2007-06-04	Pliva-Istraživački Institut D.O.O.,	Nova jedinjenja,kompozicije i metode za lečenje inflamatornih oboljenja i stanja
HRP20030324A2 (en)	2003-04-24	2005-02-28	Pliva-Istra�iva�ki institut d.o.o.	Compounds of antiinflammatory effect
WO2005030227A1 (fr)	2003-09-23	2005-04-07	Enanta Pharmaceuticals, Inc.	Derives 9a-azalide 11-3c-bicycliques
JP4737495B2 (ja) *	2004-01-14	2011-08-03	塩野義製薬株式会社	エリスロマイシン誘導体
KR20070046917A (ko) *	2004-08-12	2007-05-03	글락소스미쓰클라인 이스트라지바치키 센타 자그레브 디.오.오.	위장관의 염증성 질환의 치료를 위한 세포-특이적컨쥬게이트의 용도
US20060183696A1 (en) *	2004-08-12	2006-08-17	Pliva-Istrazivacki Institut D.O.O.	Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract
US7402568B2 (en)	2004-09-29	2008-07-22	Enanta Pharmaceuticals, Inc.	Bicyclic 9a-azalide derivatives
ES2337915T3 (es) *	2004-10-27	2010-04-30	Glaxosmithkline Istrazivacki Centar Zagreb D.O.O.	Conjugados con adtividad antiinflamatoria.
US7271155B2 (en)	2005-01-07	2007-09-18	Enanta Pharmaceuticals, Inc.	9A, 11-2C-bicyclic 9a-azalide derivatives
US20080249034A1 (en) *	2005-03-21	2008-10-09	Zambon S.P.A.	Use of Macrolides for Treating Intestinal Inflammation
WO2011116312A1 (fr) *	2010-03-19	2011-09-22	Catabasis Pharmaceuticals, Inc.	Dérivés de macrolides d'acides gras et leurs utilisations
EP2948152A4 (fr) *	2013-01-23	2016-12-14	Sphaera Pharma Private Ltd	Nouveaux composés de 11bêta-hydroxy-stéroïdes destinés à être utilisés utilisation dans la biogenèse de mitochondries et les maladies associées avec la dysfonction ou la déplétion mitochondriale
WO2016013030A2 (fr)	2014-07-23	2016-01-28	Sphaera Pharma Pvt. Ltd.	Composés hydroxystéroïdes, leurs intermédiaires, procédé de préparation, composition et utilisations de ceux-ci
GB201520419D0 (en)	2015-11-19	2016-01-06	Epi Endo Pharmaceuticals Ehf	Compounds
WO2023248010A2 (fr) *	2022-06-23	2023-12-28	Synovo Gmbh	Modulateurs ciblés de jak3 pour le traitement de maladies inflammatoires et auto-immunes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4710495A (en)	1980-07-10	1987-12-01	Otsuka Pharmaceutical Co., Ltd.	Soft steroids having anti-inflammatory activity
HU198913B (en)	1987-09-03	1989-12-28	Pliva Pharm & Chem Works	Process for producing 10-dihydro-10-deoxo-11-aza-erythronolide a-derivatives and pharmaceutical compositions containing them as active components
JPH01163124A (ja) *	1987-12-21	1989-06-27	Yamayuu Seikatsushiya:Kk	外用鎮痛消炎消腫消膿剤
SE9100342D0 (sv)	1991-02-04	1991-02-04	Astra Ab	Novel steroid esters
SE9100341D0 (sv)	1991-02-04	1991-02-04	Astra Ab	Novel steroids
GB9225923D0 (en)	1992-12-11	1993-02-03	Rhone Poulenc Rorer Ltd	New compositions of matter
DE69311742T2 (de)	1992-12-24	1998-01-08	Rhone Poulenc Rorer Ltd	Neue steroide
AU3192695A (en)	1994-08-12	1996-03-07	Taisho Pharmaceutical Co., Ltd.	Interleukin-5 production inhibitor
WO1996004919A1 (fr)	1994-08-12	1996-02-22	Taisho Pharmaceutical Co., Ltd.	Inhibiteur de production de l'interleukine-5
DE19542949A1 (de)	1995-11-17	1997-07-17	Hilti Ag	Bolzen zum Eintreiben in harte Aufnahmewerkstoffe
CA2252886C (fr)	1996-04-26	2008-02-12	Massachusetts Institute Of Technology	Methode de criblage a l'aide de trois hybrides
FR2776927B1 (fr) *	1998-04-07	2002-07-05	Univ Paris Curie	Compositions pour la vectorisation de molecules
US6288234B1 (en) *	1998-06-08	2001-09-11	Advanced Medicine, Inc.	Multibinding inhibitors of microsomal triglyceride transferase protein
WO1999064040A1 (fr) *	1998-06-08	1999-12-16	Advanced Medicine, Inc.	Nouveaux composes de macrolides de polyene et leurs utilisations
IT1306205B1 (it)	1999-01-15	2001-05-30	Zambon Spa	Macrolidi ad attivita' antiinfiammatoria.
AU2003219770B2 (en)	2002-02-15	2008-10-09	Merckle Gmbh	Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof

2001
- 2001-01-09 HR HR20010018A patent/HRP20010018A2/hr not_active Application Discontinuation
2002
- 2002-01-03 EP EP02729470A patent/EP1351973B1/fr not_active Expired - Lifetime
- 2002-01-03 HU HU0500180A patent/HUP0500180A3/hu unknown
- 2002-01-03 PL PL363478A patent/PL207636B1/pl unknown
- 2002-01-03 DE DE60235794T patent/DE60235794D1/de not_active Expired - Lifetime
- 2002-01-03 JP JP2002556599A patent/JP4474101B2/ja not_active Expired - Fee Related
- 2002-01-03 EE EEP200300293A patent/EE05333B1/xx not_active IP Right Cessation
- 2002-01-03 AT AT02729470T patent/ATE462713T1/de not_active IP Right Cessation
- 2002-01-03 US US10/250,934 patent/US7446097B2/en not_active Expired - Fee Related
- 2002-01-03 IL IL15667302A patent/IL156673A0/xx unknown
- 2002-01-03 SK SK979-2003A patent/SK9792003A3/sk unknown
- 2002-01-03 EA EA200300781A patent/EA007061B1/ru not_active IP Right Cessation
- 2002-01-03 CN CNB02804715XA patent/CN1269836C/zh not_active Expired - Fee Related
- 2002-01-03 BR BR0206347-6A patent/BR0206347A/pt not_active Application Discontinuation
- 2002-01-03 CZ CZ20031825A patent/CZ20031825A3/cs unknown
- 2002-01-03 ES ES02729470T patent/ES2342364T3/es not_active Expired - Lifetime
- 2002-01-03 CA CA002434009A patent/CA2434009C/fr not_active Expired - Fee Related
- 2002-01-03 GE GE5260A patent/GEP20053607B/en unknown
- 2002-01-03 RS YUP-552/03A patent/RS51308B/sr unknown
- 2002-01-03 WO PCT/HR2002/000001 patent/WO2002055531A1/fr not_active Ceased
- 2002-01-08 AR ARP020100040A patent/AR035727A1/es active IP Right Grant
- 2002-03-01 UA UA2003076135A patent/UA77166C2/uk unknown
2003
- 2003-08-07 BG BG108073A patent/BG108073A/bg unknown
2008
- 2008-09-16 US US12/211,213 patent/US7928078B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20040198677A1 (en)	2004-10-07
CA2434009A1 (fr)	2002-07-18
IL156673A0 (en)	2004-01-04
HK1065320A1 (en)	2005-02-18
ATE462713T1 (de)	2010-04-15
EE05333B1 (et)	2010-08-16
SK9792003A3 (en)	2004-01-08
WO2002055531A1 (fr)	2002-07-18
EE200300293A (et)	2003-10-15
HRP20010018A2 (en)	2002-12-31
EP1351973B1 (fr)	2010-03-31
CZ20031825A3 (cs)	2003-11-12
CN1491230A (zh)	2004-04-21
YU55203A (sh)	2006-03-03
AR035727A1 (es)	2004-07-07
HUP0500180A2 (en)	2006-09-28
ES2342364T3 (es)	2010-07-06
PL207636B1 (pl)	2011-01-31
HUP0500180A3 (en)	2009-12-28
CA2434009C (fr)	2009-09-29
DE60235794D1 (de)	2010-05-12
JP4474101B2 (ja)	2010-06-02
US7446097B2 (en)	2008-11-04
GEP20053607B (en)	2005-09-12
EA007061B1 (ru)	2006-06-30
UA77166C2 (en)	2006-11-15
US7928078B2 (en)	2011-04-19
EA200300781A1 (ru)	2003-12-25
EP1351973A1 (fr)	2003-10-15
PL363478A1 (en)	2004-11-15
BR0206347A (pt)	2004-02-10
CN1269836C (zh)	2006-08-16
RS51308B (sr)	2010-12-31
US20090105163A1 (en)	2009-04-23
JP2004518670A (ja)	2004-06-24

Publication	Publication Date	Title
US7928078B2 (en)	2011-04-19	Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
US7091187B2 (en)	2006-08-15	Compounds, compositions and methods for treatment of inflammatory diseases and conditions
EP1551865B1 (fr)	2009-04-22	Molecules hybrides de macrolides avec des molecules anti-inflammatoires steroidiennes/non-steroidiennes
WO1996038464A1 (fr)	1996-12-05	Conjugues antimicrobiens du sterol
RU2462472C2 (ru)	2012-09-27	Химические соединения
JP4613366B2 (ja)	2011-01-19	抗炎症活性を有するマクロライドコンジュゲート
CA1087168A (fr)	1980-10-07	17-ESTERS DE 17-.alpha.-HYDROXYGESTOGENES SUBSTANCES QUI LES CONTIENNENT, PROCEDES D'OBTENTION ET EMPLOI
EP1805202B1 (fr)	2009-12-30	Conjugues a activite anti-inflammatoire
CN101402667B (zh)	2012-05-30	糖基化修饰的一氧化氮供体型齐墩果酸类化合物、其制备方法及用途
JP2008532927A (ja)	2008-08-21	抗炎症マクロライド接合体
HK1086842B (en)	2009-04-30	Macrolide-conjugates with anti-inflammatory activity